Literature DB >> 2100361

Questionnaire for the Assessment of Symptoms and Psychological Effects in Cardiovascular Therapy (the ASPECT Scale).

S Jern1.   

Abstract

This brief review summarizes the background and principles for the development of a new psychometric instrument (Assessment of Symptoms and Psychological Effects in Cardiovascular Therapy--ASPECT Scale). The test consists of two parts, one for assessment of three aspects of global well-being (hedonic tone, relaxation, and activity) and one for evaluation of 34 commonly experienced symptomatic side-effects of cardiovascular drugs. All items are assessed by visual-analogue scales, and six clusters of symptoms have been identified: cardiac symptoms, central nervous system or cognitive symptoms, fatigue, local/cutaneous symptoms, sleeping disturbances, and other symptoms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2100361

Source DB:  PubMed          Journal:  Scand J Prim Health Care Suppl        ISSN: 0284-6020


  5 in total

1.  Impacts of components of the metabolic syndrome on health status and survival in an aged population.

Authors:  O Lindberg; R S Tilvis; T E Strandberg; J Valvanne; S Sairanen; C Ehnholm; J Tuomilehto
Journal:  Eur J Epidemiol       Date:  1997-06       Impact factor: 8.082

2.  Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis.

Authors:  Dorothy Cimino Brown; Raymond C Boston; James C Coyne; John T Farrar
Journal:  Am J Vet Res       Date:  2007-06       Impact factor: 1.156

Review 3.  Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Authors:  M I Wilde; H M Bryson; K L Goa
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

Review 4.  The effects of ACE inhibitors on cognitive function.

Authors:  A A O'Brien; C J Bulpitt
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

5.  Efficacy and tolerability of felodipine ER and diltiazem SR as monotherapy in primary hypertension: a double-blind randomized study.

Authors:  T Thulin; H Almkvist; L Berglund; T Björnsson; B Fagher; N Henningsen; M Honkavaara; V Naukkarinen; P Nordenström; J Sillanpää
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.